Side effects occur with every class of inflammatory bowel disease (IBD) medication.
Dr Raymond Cross and colleagues from the USA assessed inflammatory bowel disease (IBD) patients' subjective assessment of drug side effects using the Side effects survey (SidES).
|56% reported changes in medical management|
|Journal of Clinical Gastroenterology|
The team previously developed and tested a survey instrument in patients with asthma and psychiatric disorders.
The research team assessed disease activity, quality of life, and adherence in adult outpatients with inflammatory bowel disease.
SidES assesses the number, severity, and duration of side effects.
Prescription and over the counter medications were evaluated.
The researchers identified 39 patients from the University of Maryland inflammatory bowel disease program.
Of these, 22 patients had Crohn's disease, 12 had ulcerative colitis, and 7 had indeterminate colitis.
The team found that 27 patients reported drug side effects, of which 56% reported changes in medical management.
Disease activity increased, medication number increased, and quality of life decreased with increasing side effects scores.
The number of medications and inflammatory bowel disease drugs, use of steroids, and use of neuropsychiatrics correlated with side effects scores.
The researchers observed that side effects scores negatively correlated with the quality of life.
Dr Cross' team concluded, "Side effects were common in patients with inflammatory bowel disease from a tertiary referral center."
"Side effects are not trivial for they can result in alterations in the medical regimen and are associated with increased disease activity and decreased quality of life scores."
"The total number of medications and use of neuropsychiatric drugs and steroids are correlated with side effects scores."
"Patients have in determining whether a symptom is related to a particular drug or from a medical condition."
"Further prospective studies are needed to evaluate the impact of patient assessment of side effects on clinical outcomes in inflammatory bowel disease."